Neuroendocrine Tumors

Well Differentiated

1st Line

Operable

NET0030
Pilot Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors

Pt: Visser
Pending 1st Priority

NET0028
Phase III 177Lu-Edotretide vs Targeted MolecularTherapy w/ Everolimus in SSTR+ Neuroendocrine Tumours

Pt: Aparici
Sponsor: ITM Solucin GmbH

Inoperable

NET0032
Phase III Peptide Receptor Radionuclide Tx w/ Lu-Edotretide vs SoC in SSTR+ Neuroendocrine Tumors

Pt: Iagaru
Sponsor: ITM Solucin GmbH

2nd Line

ECOG-ACRIN: A021602
Phase III Cabozantinib vs Placebo in Advanced Neuroendocrine Tumors After Progression on Everolimus

Pt: Shabgula
ECOG-ACRIN